title: Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis.
authors.affiliation: Division of Infectious Diseases, Oregon Health & Science University, Portland, OR, USA. chous@ohsu.edu
authors.forename: Sunwen
authors.initials: S
authors.lastname: Chou
authors.forename: Gail
authors.initials: G
authors.lastname: Marousek
authors.forename: Guy
authors.initials: G
authors.lastname: Boivin
authors.forename: Nathalie
authors.initials: N
authors.lastname: Goyette
authors.forename: Mahdi
authors.initials: M
authors.lastname: Farhan
authors.forename: Jane A L
authors.initials: JA
authors.lastname: Ives
authors.forename: Robert
authors.initials: R
authors.lastname: Elston
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001483:Base Sequence; D003587:Cytomegalovirus / Q000187:drug effects / Q000235:genetics*; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000235:genetics*; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D006801:Humans; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D013997:Time Factors; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir